Early termination of drug trials.: What are the ramifications for drug companies and drug safety monitoring boards?

Gorm Boje Jensen; J Hampton

doi:10.1136/bmj.39113.534919.80

Early termination of drug trials. What are the ramifications for drug companies and drug safetymonitoring boards?

Gorm Boje Jensen, J Hampton

Hjertemedicinsk Afdeling

10 Citationer (Scopus)

Abstract

No abstract available
Udgivelsesdato: Feb 17

Originalsprog	Engelsk
Tidsskrift	B M J
Vol/bind	334
Udgave nummer	7589
Sider (fra-til)	326
ISSN	0959-8146
DOI	https://doi.org/10.1136/bmj.39113.534919.80
Status	Udgivet - 2007

Adgang til dokumentet

10.1136/bmj.39113.534919.80

http://www.bmj.com/cgi/content/full/334/7589/326

Citationsformater

@article{77c4934802264f16b834e6d29a043f1f,

title = "Early termination of drug trials.: What are the ramifications for drug companies and drug safety monitoring boards?",

abstract = "No abstract available",

author = "Jensen, {Gorm Boje} and J Hampton",

year = "2007",

doi = "10.1136/bmj.39113.534919.80",

language = "English",

volume = "334",

pages = "326",

journal = "B M J",

issn = "0959-8146",

publisher = "B M J Group",

number = "7589",

}

TY - JOUR

T1 - Early termination of drug trials.

T2 - What are the ramifications for drug companies and drug safety monitoring boards?

AU - Jensen, Gorm Boje

AU - Hampton, J

PY - 2007

Y1 - 2007

N2 - No abstract available

AB - No abstract available

U2 - 10.1136/bmj.39113.534919.80

DO - 10.1136/bmj.39113.534919.80

M3 - Journal article

C2 - 17303842

SN - 0959-8146

VL - 334

SP - 326

JO - B M J

JF - B M J

IS - 7589

ER -

Early termination of drug trials. What are the ramifications for drug companies and drug safety monitoring boards?

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater

Early termination of drug trials. What are the ramifications for drug companies and drug safetymonitoring boards?